[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353342-105":59,"doc-detail-353342-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteomic-profiling-of-extracellular-vesicle-enriched-plasma-using-mag-net-for-biomarker-discovery-in-pancreatic-ductal-adenocarcinoma","Proteomic Profiling of Extracellular Vesicle-Enriched Plasma Using Mag-Net for Biomarker Discovery in Pancreatic Ductal Adenocarcinoma","","Pancreatic ductal adenocarcinoma (PDAC) is an exceptionally aggressive cancer with limited survival and an urgent need for reliable biomarkers. Plasma proteomes were compared among PDAC patients, individuals with benign biliary pathologies (BBP), and healthy controls using Mag-Net, a magnetic-bead method enriching membrane-bound extracellular vesicles. Analyses identified dysregulated proteins and pathway signatures. PDAC samples showed enrichment for epithelial-mesenchymal transition, complement activation, hypoxia, glycolysis, and extracellular matrix remodeling. Key candidates such as SPP1, THBS2, PTX3, FBLN2, SDC1, CTSS, and VCAN increased, with LRG1 linked to severity; GPNMB, H4C1, SAA1, and CCDC47 rose progressively, supporting biomarker panel development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteomic-profiling-of-extracellular-vesicle-enriched-plasma-using-mag-net-for-biomarker-discovery-in-pancreatic-ductal-adenocarcinoma/353342/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteomic-profiling-of-extracellular-vesicle-enriched-plasma-using-mag-net-for-biomarker-discovery-in-pancreatic-ductal-adenocarcinoma/353342.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does this study aim to improve for PDAC patients?","Question",{"text":112,"@type":113},"It seeks reliable plasma biomarkers to improve clinical outcomes by enabling better diagnosis and disease tracking for pancreatic ductal adenocarcinoma (PDAC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were extracellular vesicles enriched for proteomic profiling?",{"text":117,"@type":113},"The study used Mag-Net, a magnetic-bead-based protocol that enriches membrane-bound vesicles before proteomic analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biological pathways were enriched in PDAC compared with BBP and healthy controls?",{"text":121,"@type":113},"PDAC showed enrichment for epithelial-mesenchymal transition, complement activation, hypoxia, glycolysis, and extracellular matrix remodeling pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353342,1790480784,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","This article is licensed under CC-BY 4.0   \n[pubs.acs.org/jpr](pubs.acs.org/jpr)  Article   \nProteomic Profiling of Extracellular Vesicle-Enriched Plasma Using Mag-Net for Biomarker Discovery in Pancreatic Ductal Adenocarcinoma  \nSindisiwe Buthelezi, Nnenna Elebo, Previn Naicker, Rethabile Mokoena, Sinegugu Dubazana, Ireshyn Govender, Sipho Mamputha, Andrea Ellero, Stoyan Stoychev, Jeanet Mazibuko, Dupe Ojo, Geoffrey Candy, John Devar, Stefano Cacciatore, Jones Omoshoro-Jones, and Ekene Emmanuel Nweke*  \n Cite This: J. Proteome Res. 2026, 25, 4120−4131  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer and was ranked among the top seven leading causes of cancer-related deaths in South Africa in 2020. Highlighting the urgent need for ongoing research to identify reliable biomarkers to improve clinical outcomes. This study compared the plasma proteomes of patients with PDAC, those with benign biliary pathologies (BBP), and healthy controls (HC). We used Mag-Net, a magnetic-bead-based method that enriches membrane-bound vesicles. Comparative analyses identified distinct and overlapping dysregulated proteins between PDAC, BBP, and HC. PDAC showed enrichment for epithelial-mesenchymal transition, complement activation, hypoxia, glycolysis, and extracellular matrix remodeling pathways, consistent with aggressive tumor biology. Proteins including SPP1, THBS2, PTX3, FBLN2, SDC1, CTSS, and VCAN were significantly increased in PDAC, with LRG1 showing the strongest association with disease severity. Proteins, namely GPNMB, H4C1, SAA1, and CCDC47, demonstrated progressive upregulation across disease comparisons, suggesting potential relevance to disease progression. These findings demonstrate that plasma proteomics provides discriminatory molecular insights and supports the development of population-relevant biomarker panels. While several candidate proteins show promise for inclusion in multianalyte panels, further validation in larger cohorts is necessary to establish their diagnostic and translational utility for early detection, risk stratification, and improved differential diagnosis of PDAC. KEYWORDS: pancreatic ductal adenocarcinoma (PDAC), biomarker, plasma, extracellular vesicles, Mag-Net, proteomics  \n1. INTRODUCTION  \nPancreatic Ductal Adenocarcinoma (PDAC) is an exceptionally aggressive cancer with a 5-year survival rate below 10% anda median survival time of about 6 months.1,2 PDAC became the third leading cause of cancer-related mortality worldwide in 2024, with 27,270 and 24,480 estimated mortalities in men and women, respectively.3 In South Africa, PDAC is ranked the seventh leading cause of cancer-related deaths in men and sixth in women as of 2020, with over 1900 mortalities.4 Although symptoms of PDAC include jaundice, abdominal pain, nausea, vomiting and weight loss, they mostly manifest in advanced  \nsges of the disease.5  \n( 85%) present with  \nHence, the majority of the unresectable stage  \nPDAC patients of the disease.6  \nSurgery is the best way to treat PDAC, but this treatment is limited to resectable cases. Other treatment options include chemotherapy, radiation and immunotherapy. Although the mean age at diagnosis of PDAC is around 65 years, recent data suggest that diagnoses of younger individuals with PDAC are on the rise.7,8 Environmental and lifestyle factors such as obesity, diabetes and excessive alcohol use have been shown to contribute to the increasing frequency of young-onset  \nPDAC.7,9 Other risk factors include genetic factors, chronic pancreatitis, among others.10  \nThe poor clinical prognosis of PDAC stems from the absence of effective early diagnostic markers and its continued resistance to available therapies. 11 Proteomic profiling of biological samples has proven valuable for biomarker discovery in c","cbCaiuEXHM9tDocH","https://ap.wps.com/l/cbCaiuEXHM9tDocH","pdf",4431224,12,"English","# Abstract\n## Study design and cohort comparisons\n## Biomarker candidates and pathway findings\n## Implications for biomarker panels and validation","[{\"question\":\"What does this study aim to improve for PDAC patients?\",\"answer\":\"It seeks reliable plasma biomarkers to improve clinical outcomes by enabling better diagnosis and disease tracking for pancreatic ductal adenocarcinoma (PDAC).\"},{\"question\":\"How were extracellular vesicles enriched for proteomic profiling?\",\"answer\":\"The study used Mag-Net, a magnetic-bead-based protocol that enriches membrane-bound vesicles before proteomic analysis.\"},{\"question\":\"Which biological pathways were enriched in PDAC compared with BBP and healthy controls?\",\"answer\":\"PDAC showed enrichment for epithelial-mesenchymal transition, complement activation, hypoxia, glycolysis, and extracellular matrix remodeling pathways.\"}]","Proteomic Profiling of Extracellular Vesicle-Enriched Plasma Using Mag-Net for Biomarker Discovery in Pancreatic Ductal Adenocarcinoma | PDF",1790104807,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dbff8120d13f420fc259e45af78a213.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b815f40342f92fe58f56680609d4c44.webp",982,1295,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1832f42784596378b6265d09db488c5a.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc9b5149e7725928d959b0d17fc439b3.webp",980,1292]